{
    "2021-11-17": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Europe Approves AbbVie's Skyrizi For Second Indication",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Skyrizi",
                        "Approval",
                        "Second Indication"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "1 Dividend Stock to Help You Fight Inflation",
                "features": {
                    "keywords": [
                        "Dividend",
                        "Stock",
                        "Inflation"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows",
                "features": {
                    "keywords": [
                        "Investors",
                        "Johnson & Johnson",
                        "Spinoff",
                        "History"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZIÂ® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Immunology",
                        "European Union",
                        "SKYRIZI",
                        "Approval",
                        "Psoriatic Arthritis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}